A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients (Experience of clinical trials of KPS-0373)

Clinical Trial Description

n/a

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01970137
Study type	Interventional
Source	Kissei Pharmaceutical Co., Ltd.
Contact
Status	Completed
Phase	Phase 3

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01970098` - A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
	Completed	`NCT02889302` - An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
	Completed	`NCT04107740` - C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration	Phase 4
	Completed	`NCT01970124` - A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
	Completed	`NCT01970111` - An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 3
	Completed	`NCT00863538` - Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 2
	Completed	`NCT01004016` - A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)	Phase 2